{"id":"surufatinib-plus-toripalimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Palmar-plantar erythrodysesthesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This combination pairs a multi-targeted tyrosine kinase inhibitor with an immune checkpoint inhibitor. Surufatinib targets fibroblast growth factor receptors, vascular endothelial growth factor receptors, and RET to suppress tumor vasculature and proliferation. Toripalimab blocks PD-1 on T cells, releasing immune suppression and enabling the immune system to attack cancer cells. Together, they provide both direct anti-angiogenic/anti-proliferative effects and immune activation.","oneSentence":"Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:01.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic neuroendocrine tumors (NET)"},{"name":"Advanced hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Pancreatic Cancer Resectable","enrollment":30},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06654947","phase":"PHASE2","title":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-01","conditions":"Biliary Tract Cancer","enrollment":23},{"nctId":"NCT06313554","phase":"NA","title":"Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-20","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":63},{"nctId":"NCT05015621","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2021-09-18","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":194},{"nctId":"NCT06062485","phase":"PHASE2","title":"Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10","conditions":"Ampullary Carcinoma","enrollment":30},{"nctId":"NCT04653480","phase":"PHASE2","title":"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-02-01","conditions":"Colorectal Cancer","enrollment":61},{"nctId":"NCT04169672","phase":"PHASE2","title":"Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2019-12-26","conditions":"Advanced Solid Tumors","enrollment":248},{"nctId":"NCT04996771","phase":"PHASE1, PHASE2","title":"Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-11-09","conditions":"Small Cell Lung Carcinoma","enrollment":88},{"nctId":"NCT05003037","phase":"PHASE2","title":"Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2021-12-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":106},{"nctId":"NCT05056116","phase":"NA","title":"A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2021-09-01","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT05030246","phase":"PHASE2","title":"Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-07-14","conditions":"Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer","enrollment":72},{"nctId":"NCT04955886","phase":"PHASE2","title":"Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2021-08","conditions":"Nasopharyngeal Carcinoma","enrollment":14},{"nctId":"NCT04524884","phase":"PHASE2","title":"Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-10-01","conditions":"Thyroid Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HMPL-012 plus JS001"],"phase":"phase_3","status":"active","brandName":"Surufatinib plus Toripalimab","genericName":"Surufatinib plus Toripalimab","companyName":"Hutchison Medipharma Limited","companyId":"hutchison-medipharma-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses. Used for Advanced or metastatic neuroendocrine tumors (NET), Advanced hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}